Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. T...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. Elzéar Blvd. West, Laval, Canada

Trigga_tha_Gambler Jun. 25 at 4:31 PM

$BHC In at 5.30

0 · Reply

truckersam Jun. 25 at 3:58 PM

$BHC What's the Occasion

1 · Reply

Coolhat1 Jun. 24 at 8:34 PM

$BHC $MU beat earning our moment was over back to 4 we go

0 · Reply

FU2 Jun. 24 at 6:04 PM

$BHC sector rotation, just need some positive

0 · Reply

btradingwarehouse Jun. 24 at 4:59 PM

$BHC ...2BULLS... ... Just play opossum Do not touch it All good ...

0 · Reply

Contrarian_Dan Jun. 23 at 9:12 PM

$BHC I wonder if the sell-off into the $4S is because the Phase 3 trials for Larsucosterol aren’t meeting their efficacy endpoints?

1 · Reply

Coolhat1 Jun. 23 at 8:16 PM

$BHC finally a Green Day. I can’t wait until the day blco sold would be the best day of my life

0 · Reply

FU2 Jun. 23 at 1:26 PM

$BHC some funds probably have to sell now that it's solidly under $5. See if the volume stays above average.

0 · Reply

Coolhat1 Jun. 23 at 4:14 AM

$BHC this stock wrecked endless amount of people hope we can be whole again it super unfair

0 · Reply

Coolhat1 Jun. 22 at 8:46 PM

$BHC why is it tanking so bad what gives

0 · Reply

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

May 20, 2026, 9:30 AM EDT - 5 weeks ago

Bausch Health Companies Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 4:15 PM EDT - 5 weeks ago

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

May 19, 2026, 10:25 AM EDT - 5 weeks ago

Bausch Health Companies Transcript: Barclays 30th Annual Leveraged Finance Conference 2026

May 19, 2026, 9:00 AM EDT - 5 weeks ago

Bausch Health Companies Transcript: AGM 2026

May 19, 2026, 7:00 AM EDT - 5 weeks ago

Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference

May 12, 2026, 4:15 PM EDT - 6 weeks ago

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Apr 29, 2026, 5:00 PM EDT - 2 months ago

Bausch Health Companies Earnings Call Transcript: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 2 months ago

Bausch Health Companies Slides: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 2 months ago

Bausch Health Companies Earnings release: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 2 months ago

Bausch Health Companies Quarterly report: Q1 2026

2026-04-29T20:33:36.000Z - 2 months ago

Bausch Health reports Q1 non-GAAP EPS 78c, consensus 69c

BHC

2026-04-29T20:29:28.000Z - 2 months ago

Bausch Health sees 2026 revenue $10.67B-$10.92B, consensus $10.68B

BHC

Apr 29, 2026, 4:05 PM EDT - 2 months ago

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Bausch Health Companies Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Bausch Health Companies Proxy statement: Proxy filing

Apr 8, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update

Apr 7, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

2026-02-25T10:15:55.000Z - 4 months ago

Bausch Health price target lowered to $7 from $8 at Barclays

BHC

Feb 23, 2026, 8:00 AM EST - 4 months ago

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

Feb 19, 2026, 8:00 AM EST - 4 months ago

Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres

Feb 18, 2026, 5:00 PM EST - 4 months ago

Bausch Health Companies Earnings Call Transcript: Q4 2025

Feb 18, 2026, 5:00 PM EST - 4 months ago

Bausch Health Companies Annual report: Q4 2025

Feb 18, 2026, 5:00 PM EST - 4 months ago

Bausch Health Companies Earnings release: Q4 2025

Feb 18, 2026, 5:00 PM EST - 4 months ago

Bausch Health Companies Slides: Q4 2025

2026-02-18T21:21:45.000Z - 4 months ago

Bausch Health reports Q4 EPS (30c) vs. 25c a year ago

BHC

Feb 18, 2026, 4:05 PM EST - 4 months ago

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Feb 17, 2026, 7:00 AM EST - 4 months ago

Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference

Feb 11, 2026, 8:00 AM EST - 4 months ago

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program

2026-02-02T19:40:25.000Z - 5 months ago

NY AG announces settlement with Lannett and Bausch Health

BHC

2026-01-23T18:55:29.000Z - 5 months ago

Bausch’s RED-C miss raises pressure ahead of Xifaxan LOE, Truist says

BHC

Jan 23, 2026, 7:52 AM EST - 5 months ago

Bausch Health's brain dysfunction treatment fails late-stage trial

2026-01-23T12:50:15.000Z - 5 months ago

Bausch Health results from Phase 3 RED-C program did not meet primary endpoint

BHC

Jan 23, 2026, 7:45 AM EST - 5 months ago

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

Jan 21, 2026, 7:00 AM EST - 5 months ago

Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026

Jan 14, 2026, 6:45 PM EST - 5 months ago

Bausch Health Companies Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 5 months ago

Bausch Health Companies Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-07T12:20:14.000Z - 6 months ago

Bausch Health price target raised to $8 from $7 at Truist

BHC

Jan 5, 2026, 7:00 AM EST - 6 months ago

Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 5:35 PM EST - 6 months ago

Bausch Health Announces Final Results and Expiration of Exchange Offers

Dec 8, 2025, 7:22 PM EST - 7 months ago

Bausch Health Announces Early Exchange Offer Results for Exchange Offers

2025-12-08T21:31:57.000Z - 7 months ago

Bausch Health initiated with an Equal Weight at Barclays

BHC

Dec 2, 2025, 10:50 AM EST - 7 months ago

Bausch Health Companies Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-01T17:00:16.000Z - 7 months ago

Bausch Health rises 14.8%

BHC

2025-12-01T15:05:36.000Z - 7 months ago

Bausch Health rises 11.3%

BHC

2025-12-01T12:50:29.000Z - 7 months ago

Bausch Health’s Solta Medical completes Wuhan Shibo acquisition

BHC

Dec 1, 2025, 7:00 AM EST - 7 months ago

Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China

2025-11-24T12:50:20.000Z - 7 months ago

Bausch Health launches offers to exchange senior secured notes

BHC

Nov 24, 2025, 7:05 AM EST - 7 months ago

Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

Nov 18, 2025, 7:00 AM EST - 7 months ago

Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 8:18 AM EST - 8 months ago

Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Nov 13, 2025, 7:00 AM EST - 8 months ago

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Nov 5, 2025, 8:00 AM EST - 8 months ago

Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease

Nov 3, 2025, 4:30 PM EST - 8 months ago

Bausch + Lomb to Hold Investor Day on Nov. 13

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Bausch Health Companies Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Bausch Health Companies Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Bausch Health Companies Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 8 months ago

Bausch Health Companies Slides: Q3 2025

Oct 29, 2025, 4:05 PM EDT - 8 months ago

Bausch Health Announces Third Quarter 2025 Results

Oct 9, 2025, 7:00 AM EDT - 9 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

Sep 30, 2025, 8:00 AM EDT - 9 months ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 7:00 AM EDT - 9 months ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 11, 2025, 8:35 AM EDT - 10 months ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 10 months ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 10 months ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 10 months ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 27, 2025, 8:00 AM EDT - 10 months ago

Bausch Health Companies Proxy statement: Proxy Filing

Aug 26, 2025, 8:00 AM EDT - 10 months ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Aug 21, 2025, 8:02 AM EDT - 11 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 18, 2025, 5:48 PM EDT - 11 months ago

Bausch + Lomb board members resign after Icahn agreement ends

Aug 15, 2025, 2:30 PM EDT - 11 months ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Bausch Health Companies Proxy statement: Proxy Filing

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Earnings Call Transcript: Q2 2025

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Quarterly report: Q2 2025

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Earnings release: Q2 2025

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Slides: Q2 2025

Jul 30, 2025, 4:05 PM EDT - 11 months ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 7:00 AM EDT - 11 months ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 11 months ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 11 months ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 1 year ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Trigga_tha_Gambler Jun. 25 at 4:31 PM

$BHC In at 5.30

0 · Reply

truckersam Jun. 25 at 3:58 PM

$BHC What's the Occasion

1 · Reply

Coolhat1 Jun. 24 at 8:34 PM

$BHC $MU beat earning our moment was over back to 4 we go

0 · Reply

FU2 Jun. 24 at 6:04 PM

$BHC sector rotation, just need some positive

0 · Reply

btradingwarehouse Jun. 24 at 4:59 PM

$BHC ...2BULLS... ... Just play opossum Do not touch it All good ...

0 · Reply

Contrarian_Dan Jun. 23 at 9:12 PM

$BHC I wonder if the sell-off into the $4S is because the Phase 3 trials for Larsucosterol aren’t meeting their efficacy endpoints?

1 · Reply

Coolhat1 Jun. 23 at 8:16 PM

$BHC finally a Green Day. I can’t wait until the day blco sold would be the best day of my life

0 · Reply

FU2 Jun. 23 at 1:26 PM

$BHC some funds probably have to sell now that it's solidly under $5. See if the volume stays above average.

0 · Reply

Coolhat1 Jun. 23 at 4:14 AM

$BHC this stock wrecked endless amount of people hope we can be whole again it super unfair

0 · Reply

Coolhat1 Jun. 22 at 8:46 PM

$BHC why is it tanking so bad what gives

0 · Reply

Contrarian_Dan Jun. 22 at 5:00 PM

$BHC is a low 4 print coming?! Probably…

0 · Reply

FU2 Jun. 22 at 3:49 PM

$BHC I feel a share price run coming. That was a good beat down for this month. 🤑🤑🤑

0 · Reply

Broview Jun. 21 at 2:54 PM

$BHC cut debt! One of the most leveraged pharmaceuticals? Extremely dangerous?

1 · Reply

Coolhat1 Jun. 20 at 4:15 AM

$BHC the healthcare/ pharma section as a whole is being hit hard and fed rate hike doesn’t help company with debt at all. I still see this as a great opportunity with ample run way blco sold for 15 billion or more ev and we are cooking

0 · Reply

btradingwarehouse Jun. 18 at 9:31 PM

$BHC ...2 BULLS... ...to my fellow beaten down Champs... ... Remember this for fuck's sake: This will NEVER go bankrupt !!! This stock is bitch and Mr. P is pimp that won't let it go Mr. P is in FULL !!! control of this beauty for CONTROLING LOSSES Other big money can't fight Mr. P Mr. P is holding this under $10 as long as his portfolio needs it Without BLCO this ain't moving shit...ok...(BLCO>$21) Well...what to do ?: If you are IN-stay IN...do NOT sell !!!...got it ?!! If you are IN-want average...Hell nooo !!! If you want to get IN..do NOT even think 'bout it !!! If you need more of my BS feel free to contact me I am almost 100% confident that my take is the right one Also my unrealized loss is ~$350K and I still have smile upon my face Stay smart strong smile leonardo

1 · Reply

Sciguy67 Jun. 18 at 3:12 PM

$BHC is bankruptcy in its near future

0 · Reply

Coolhat1 Jun. 18 at 2:55 PM

$BHC I have been holding on to this too long, honestly what do you guys think I should do take my losses and move on or wait a couple more years it’s been a painful hold. Serious answers only

1 · Reply

RomanFord Jun. 18 at 2:51 PM

$BHC if this doesn't close above 4.75 we could see this go all the way down to 2.00

1 · Reply

Stock_Spectator Jun. 18 at 2:27 PM

$BHC a new one year low…

0 · Reply

JJW Jun. 18 at 2:12 PM

$BHC This has got to be the worst management team in history. No plan after all these years. Unbelievable!

0 · Reply

Coolhat1 Jun. 18 at 2:04 PM

$BHC please do more scholarship this shit is tanking hard

0 · Reply

AKTN Jun. 18 at 3:23 AM

$TAK $BHC paging Takeda, you wanted Salix back in 2016 for $9.1B, now you can have the whole shitheap BHC for under $1.8B.

0 · Reply

Market Cap	1.80B
Revenue (ttm)	10.27B
Net Income (ttm)	157.00M
EPS (ttm)	N/A
PE Ratio	1.19
Forward PE	1.15
Profit Margin	1.53%
Debt to Equity Ratio	-19.19

Volume	2,353,300
Avg Vol	1,874,876
Day's Range	N/A - N/A
Shares Out	374.02M
Stochastic %K	31%
Beta	0.40
Analysts	Hold
Price Target	$7.50